Low-dose dual blockade of the renin-angiotensin system improves tubular status in non-diabetic proteinuric patients

Scandinavian Journal of Urology and Nephrology

Volumn 39, Issue 6, 2005, Pages 511-517

  Renke, Marcin ^a   Tylicki, Leszek ^a   Rutkowski, Przemyslaw ^a   Wojnarowski, Klaudiusz ^a   Lysiak Szydlowska, Wieslawa ^a   Rutkowski, Boleslaw ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

1 microglobulin; Angiotensin II receptor antagonist; Angiotensin converting enzyme inhibitor; Combination treatment; Primary glomerulonephritis; Transforming growth factor 1; Tubule

Indexed keywords

ALPHA 1 MICROGLOBULIN; BENAZEPRIL; LOSARTAN; TRANSFORMING GROWTH FACTOR BETA2;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG MEGADOSE; FEMALE; GLOMERULONEPHRITIS; HUMAN; MALE; PRIORITY JOURNAL; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; STANDARDIZATION; SYSTEMIC CIRCULATION; URINARY EXCRETION;

ADOLESCENT; ADULT; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BENZAZEPINES; BIOLOGICAL MARKERS; CREATININE; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; LOSARTAN; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; NEPHELOMETRY AND TURBIDIMETRY; PROTEINURIA; RENIN-ANGIOTENSIN SYSTEM; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TREATMENT OUTCOME; TRYPSIN INHIBITOR, KUNITZ SOYBEAN;

EID: 28444462925     PISSN: 00365599     EISSN: 16512065     Source Type: Journal    
DOI: 10.1080/00365590510031264     Document Type: Article

References (21)

1. Taal M, Brenner B. Renoprotective benefits of RAS inhibition: from ACEI to angiotensin II antagonists. Kidney Int 2000;57:1803-17.
2. Taal M, Brenner B. Combination ACEI and ARB therapy: additional benefit in renoprotection. Curr Opin Nephrol Hypertens 2002;11:377-81.
3. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003;361:117-24.
4. Tylicki L, Rutkowski P, Renke M, Rutkowski B. Renoprotective effect of small doses of losartan and enalapril in patients with primary glomerulonephritis. Am J Nephrol 2002;22:356-62.
5. Rutkowski P, Tylicki L, Renke M, Korejwo G, Zdrojewski Z, Rutkowski B. Low-dose dual blockade of the renin-angiotensin system in patients with primary glomerulonephritis. Am J Kidney Dis 2004;43:260-8.
6. Risdon R, Sloper J, de Wardener H. Relationship between renal function and histological changes found in renal biopsy specimens from patients with persistent glomerular nephritis. Lancet 1968;ii:363-6.
7. Krusell LR, Christensen CK, Pedersen OL. Alpha-adrenoceptor blockade in patients with mild to moderate hypertension: long-term renal effects of doxazosin. J Cardiovasc Pharmacol 1992;20:440-4.
8. Iodice C, Balleta MM, Minutolo R, Giannattasio P, Tuccillo S, Bellizzi V, et al. Maximal suppression of renin-angiotensin system in nonproliferative glomerulonephritis. Kidney Int 2003;63:2214-2221.
9. Becker G, Hewitson T. The role of tubulointerstitial injury in chronic renal failure. Curr Opin Nephrol Hypertens 2000;9:133-8.
10. D'Amico G. Tubulo-interstitial damage in glomerular diseases: its role in the progression of the renal damage. Nephrol Dial Transplant 1998;13(Suppl 1):80-5.
11. Healy E, Brady H. Role of tubule epithelial cells in the pathogenesis of tubulointerstitial fibrosis induced by glomerular disease. Curr Opin Nephrol Hypertens 1998;7:525-30.
12. Bazzi C, Petrini C, Rizza V, Arrigo G, Napodano P, Paparella M, et al. Urinary N-acetylglucosaminidase excretion is a marker of tubular cell dysfunction and a predictor of outcome in primary glomerulonephritis. Nephrol Dial Transplant 2002;17:1890-6.
13. Bazzi C, Petrini C, Rizza V, Arrigo G, Beltrame A, Pisano L, et al. Urinary excretion of IgG and alfa-1 microglobulin predicts clinical course better than extent of proteinuria in membranous nephropathy. Am J Kidney Dis 2001,38:240-8.
14. Renke M, Tylicki L, Rutkowski P, Rutkowski B. Angiotensin II receptor antagonists (ARB) and angiotensin II converting enzyme inhibitors (ACEI) in low doses: alone or both for treatment of primary glomerulonephritis. Scand J Urol Nephrol 2004;38:427-33.
15. Holdt-Lehmann B, Lehmann A, Korten G, Nagel H, Nizze H, Schuff-Werner P. Diagnostic value of urinary alanine aminopeptidase and N-acetyl-beta-D- glucosaminidase in comparison to alfa-1 microglobulin as a marker in evaluating tubular dysfunction in glomerulonephritis patients. Clin Chim Acta 2000;297:93-102.
16. Basile D. The transforming growth factor beta system in kidney disease and repair: recent progress and future directions. Curr Opin Nephrol Hypertens 1999;8:21-30.
17. Agarwal R, Siva S, Dunn S, Sharma K. Add-on angiotensin II receptor blockade lowers urinary transforming growth factor-beta levels. Am J Kidney Dis 2002;39:486-92.
18. Peters H, Border W, Noble N. Targeting TGF-beta overexpression in renal disease: maximizing the antifibrotic action of angiotensin II blockade. Kidney Int 1998;54:1570-80.
19. Haramaki R, Tamaki K, Fujisawa M, Ikedo H, Haramaki N, Okuda S. Steroid therapy and urinary transforming growth factor beta-1 in IgA nephropathy. Am J Kidney Dis 2001;38:1191-8.
20. Houlihan C, Akdeniz A, Tsalamandris C, Cooper M, Jerums G, Gilbert R. Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes and elevated albumin excretion rate. Diabetes Care 2002;25:1072-7.
21. Komine N, Khang S, Wead L, Blantz R, Gabbai F. Effect of combining an ACE inhibitor and an angiotensin II receptor blocker on plasma and kidney tissue angiotensin II levels. Am J Kidney Dis 2002;39:159-64.